93 related articles for article (PubMed ID: 23218775)
1. A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid.
Setoguchi M; Iimura S; Sugimoto Y; Yoneda Y; Chiba J; Watanabe T; Muro F; Iigo Y; Takayama G; Yokoyama M; Taira T; Aonuma M; Takashi T; Nakayama A; Machinaga N
Bioorg Med Chem; 2013 Jan; 21(1):42-61. PubMed ID: 23218775
[TBL] [Abstract][Full Text] [Related]
2. Identification of trans-4-[1-[[7-fluoro-2-(1-methyl-3-indolyl)-6-benzoxazolyl]acetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid as a potent, orally active VLA-4 antagonist.
Setoguchi M; Iimura S; Sugimoto Y; Yoneda Y; Chiba J; Watanabe T; Muro F; Iigo Y; Takayama G; Yokoyama M; Taira T; Aonuma M; Takashi T; Nakayama A; Machinaga N
Bioorg Med Chem; 2012 Feb; 20(3):1201-12. PubMed ID: 22261021
[TBL] [Abstract][Full Text] [Related]
3. Discovery of trans-4-[1-[[2,5-Dichloro-4-(1-methyl-3-indolylcarboxamido)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid: an orally active, selective very late antigen-4 antagonist.
Muro F; Iimura S; Sugimoto Y; Yoneda Y; Chiba J; Watanabe T; Setoguchi M; Iigou Y; Matsumoto K; Satoh A; Takayama G; Taira T; Yokoyama M; Takashi T; Nakayama A; Machinaga N
J Med Chem; 2009 Dec; 52(24):7974-92. PubMed ID: 19891440
[TBL] [Abstract][Full Text] [Related]
4. Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist.
Muro F; Iimura S; Yoneda Y; Chiba J; Watanabe T; Setoguchi M; Iigou Y; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
Bioorg Med Chem; 2008 Dec; 16(23):9991-10000. PubMed ID: 18952443
[TBL] [Abstract][Full Text] [Related]
5. Improvement of pulmonary function by oral treatment with a VLA-4 antagonist in a mouse asthmatic model.
Takayama G; Matsumoto K; Taira T; Aonuma M; Yokoyama M; Iigo Y; Takashi T
J Pharmacol Sci; 2013; 121(2):172-5. PubMed ID: 23419271
[TBL] [Abstract][Full Text] [Related]
6. A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid.
Muro F; Iimura S; Yoneda Y; Chiba J; Watanabe T; Setoguchi M; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
Bioorg Med Chem; 2009 Feb; 17(3):1232-43. PubMed ID: 19124247
[TBL] [Abstract][Full Text] [Related]
7. A novel synthetic approach to very late antigen-4 antagonist trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid via tert-butyl trans-[(4S)-Methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate as a key intermediate.
Chiba J; Machinaga N
Chem Pharm Bull (Tokyo); 2011; 59(5):574-8. PubMed ID: 21532195
[TBL] [Abstract][Full Text] [Related]
8. A concise synthesis of a very late antigen-4 antagonist trans-4-[1-[[2,5-dichloro-4-(1-methyl-3-indolylcarboxyamide)phenyl]acetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid via reductive etherification.
Chiba J; Muro F; Setoguchi M; Machinaga N
Chem Pharm Bull (Tokyo); 2012; 60(7):882-6. PubMed ID: 22790822
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of eosinophilia in vivo by a small molecule inhibitor of very late antigen (VLA)-4.
Okigami H; Takeshita K; Tajimi M; Komura H; Albers M; Lehmann TE; Rölle T; Bacon KB
Eur J Pharmacol; 2007 Mar; 559(2-3):202-9. PubMed ID: 17234179
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent, orally bioavailable pyrimidine VLA-4 antagonist effective in a sheep asthma model.
Semko CM; Chen L; Dressen DB; Dreyer ML; Dunn W; Farouz FS; Freedman SB; Holsztynska EJ; Jefferies M; Konradi AW; Liao A; Lugar J; Mutter L; Pleiss MA; Quinn KP; Thompson T; Thorsett ED; Vandevert C; Xu YZ; Yednock TA
Bioorg Med Chem Lett; 2011 Mar; 21(6):1741-3. PubMed ID: 21316228
[TBL] [Abstract][Full Text] [Related]
11. 4-(Pyrrolidinyl)methoxybenzoic acid derivatives as a potent, orally active VLA-4 antagonist.
Chiba J; Iimura S; Yoneda Y; Sugimoto Y; Horiuchi T; Muro F; Ochiai Y; Ogasawara T; Tsubokawa M; Iigou Y; Takayama G; Taira T; Takata Y; Yokoyama M; Takashi T; Nakayama A; Machinaga N
Chem Pharm Bull (Tokyo); 2006 Nov; 54(11):1515-29. PubMed ID: 17077548
[TBL] [Abstract][Full Text] [Related]
12. Improving solubility and chemical stability of natural compounds for medicinal use by incorporation into liposomes.
Coimbra M; Isacchi B; van Bloois L; Torano JS; Ket A; Wu X; Broere F; Metselaar JM; Rijcken CJ; Storm G; Bilia R; Schiffelers RM
Int J Pharm; 2011 Sep; 416(2):433-42. PubMed ID: 21291975
[TBL] [Abstract][Full Text] [Related]
13. Identified a morpholinyl-4-piperidinylacetic acid derivative as a potent oral active VLA-4 antagonist.
Chiba J; Machinaga N; Takashi T; Ejima A; Takayama G; Yokoyama M; Nakayama A; Baldwin JJ; McDonald E; Moriarty KJ; Sarko CR; Saionz KW; Swanson R; Hussain Z; Wong A
Bioorg Med Chem Lett; 2005 Jan; 15(1):41-5. PubMed ID: 15582407
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and analysis of a polyethelene glycol-modified (PEGylated) small molecule inhibitor of integrin {alpha}4{beta}1 with improved pharmaceutical properties.
Pepinsky RB; Lee WC; Cornebise M; Gill A; Wortham K; Chen LL; Leone DR; Giza K; Dolinski BM; Perper S; Nickerson-Nutter C; Lepage D; Chakraborty A; Whalley ET; Petter RC; Adams SP; Lobb RR; Scott DM
J Pharmacol Exp Ther; 2005 Feb; 312(2):742-50. PubMed ID: 15485895
[TBL] [Abstract][Full Text] [Related]
15. Effects of the very late adhesion molecule 4 antagonist WAY103 on human peripheral blood eosinophil vascular cell adhesion molecule 1-dependent functions.
Sedgwick JB; Jansen KJ; Kennedy JD; Kita H; Busse WW
J Allergy Clin Immunol; 2005 Oct; 116(4):812-9. PubMed ID: 16210055
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of benzoic acid derivatives as potent, orally active VLA-4 antagonists.
Chiba J; Iimura S; Yoneda Y; Watanabe T; Muro F; Tsubokawa M; Iigou Y; Satoh A; Takayama G; Yokoyama M; Takashi T; Nakayama A; Machinaga N
Bioorg Med Chem; 2007 Feb; 15(4):1679-93. PubMed ID: 17194595
[TBL] [Abstract][Full Text] [Related]
17. The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma.
Ravensberg AJ; Luijk B; Westers P; Hiemstra PS; Sterk PJ; Lammers JW; Rabe KF
Allergy; 2006 Sep; 61(9):1097-103. PubMed ID: 16918513
[TBL] [Abstract][Full Text] [Related]
18. Sulphonamide-based small molecule VLA-4 antagonists.
Stasiak M; Mehlin C; Boni E; Vaisar T; Little T; Kim HO; Qabar M
Bioorg Med Chem Lett; 2003 Nov; 13(21):3875-8. PubMed ID: 14552799
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists.
Takeda K; Terauchi T; Hashizume M; Shikata K; Taguchi R; Murata-Tai K; Fujisawa M; Takahashi Y; Shin K; Ino M; Shibata H; Yonaga M
Bioorg Med Chem; 2012 Nov; 20(22):6559-78. PubMed ID: 23062820
[TBL] [Abstract][Full Text] [Related]
20. Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalanine (MK-0617), a highly potent and orally active VLA-4 antagonist.
Venkatraman S; Lebsack AD; Alves K; Gardner MF; James J; Lingham RB; Maniar S; Mumford RA; Si Q; Stock N; Treonze KM; Wang B; Zunic J; Munoz B
Bioorg Med Chem Lett; 2009 Oct; 19(19):5803-6. PubMed ID: 19713111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
